News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

What are some of the new therapies discussed at ASH 2024?

Original Publication Date
Article Source
External Web Content
A roundtable discussion on anemia management in myelodysplastic syndromes featuring moderator Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center; Amy DeZern, MD, MHS, Johns Hopkins Medicine; Tiffany Tanaka, MD, of the University of California San…

Maintenance Therapy in AML: What Is the Future Potential?

Original Publication Date
Article Source
External Web Content
ABSTRACT Over the last decade, there have been significant advancements in the treatment for patients with acute myeloid leukemia (AML) including the addition of novel, targeted agents to intensive or nonintensive chemotherapy regimens. However, despite this, the majority of…

Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia

Original Publication Date
Article Source
External Web Content
Significant progress in the characterization of molecular pathogenic events in acute myeloid leukemia (AML) has led to better characterization of prognosis and identification of subsets that are more likely to benefit from currently available strategies. Furthermore, deciphering…

ACROBAT interim results support AlloHeme for relapse prediction in AML, MDS

Original Publication Date
Article Source
External Web Content
Interim results of the ACROBAT study suggest that increasing microchimerism and loss of complete chimerism may indicate relapse risk in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The findings were presented in an oral abstract1 at the 2025…

Jane Biehl: Moving Slower and Slower After Myelodysplastic Syndrome

Original Publication Date
Article Source
External Web Content
I have honestly been frustrated lately. I am slowing down increasingly, and it has even become noticeable to others. I wrote an article in November about how nice it was to slow down and smell the roses. But now it seems like too much. In my previous life (before cancer), I moved…

Genome sequencing in the management of myelodysplastic syndromes and related disorders

Original Publication Date
Article Source
External Web Content
Abstract Myeloid neoplasms originate from the clonal proliferation of hematopoietic stem cells, which is driven by the acquisition of somatic genetic mutations. Within these disorders, myelodysplastic syndromes (MDS) are specifically characterized by morphological abnormalities…

Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications

Original Publication Date
Article Source
External Web Content
Key Points The ICC and WHO5 differently classify 64% of TP53-mutated disease due to distinct criteria for multihit TP53 mutations and TP53-mutated AML. MDS with a single TP53 mutation and CK is similar to MDS with biallelic TP53 abnormalities, whereas TP53-mutated AML is distinct…

Life After MDS and Accomplishing Your Goals

Original Publication Date
Article Source
External Web Content
Several years ago, I wrote an emotionally difficult article titled "Will I Reach My Goal?" It was about a book I was writing. The book describes my life and what it was like being hard of hearing in the 60s and 70s without any support in the schools. It covers my experiences…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families